Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer

<p>Proteins identified in RNA pulldown and mass spectrometry analysis with FZR1[m6A] or FZR1[A].</p>

Saved in:

书目详细资料
主要作者:	Jiachun Su (16990970) (author)
其他作者:	Rui Li (16990973) (author), Ziming Chen (16990976) (author), Shaoqiu Liu (16990979) (author), Hongzhe Zhao (16990982) (author), Shuang Deng (16990985) (author), Lingxing Zeng (16990988) (author), Zilan Xu (16990991) (author), Sihan Zhao (16990994) (author), Yifan Zhou (16990997) (author), Mei Li (16991000) (author), Xiaowei He (16991003) (author), Ji Liu (16991006) (author), Chunling Xue (16991009) (author), Ruihong Bai (16991012) (author), Lisha Zhuang (16991015) (author), Quanbo Zhou (16991018) (author), Shaoping Zhang (16991021) (author), Rufu Chen (16991024) (author), Xudong Huang (16991027) (author), Dongxin Lin (16991030) (author), Jian Zheng (11732682) (author), Jialiang Zhang (16991033) (author)
出版:	2025
主题:	Cancer Cancer Risk Factors Molecular and Cellular Biology Therapeutic Research and Development Chemotherapy Drug Resistance Regulation of gene expression in drug resistance Epigenetics Gastrointestinal Cancers Pancreatic cancer
标签:	添加标签没有标签, 成为第一个标记此记录!

相似书籍

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
由: Dahihm Kim (16546203)
出版: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
由: Dahihm Kim (16546203)
出版: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
由: Dahihm Kim (16546203)
出版: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
由: Dahihm Kim (16546203)
出版: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
由: Dahihm Kim (16546203)
出版: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
由: Dahihm Kim (16546203)
出版: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
由: Dahihm Kim (16546203)
出版: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
由: Chong Kin Liam (15331321)
出版: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
由: Chong Kin Liam (15331321)
出版: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
由: Chong Kin Liam (15331321)
出版: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
由: Chong Kin Liam (15331321)
出版: (2025)

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
由: Gregory L. Beatty (15087193)
出版: (2025)

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
由: Gregory L. Beatty (15087193)
出版: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
由: Xiaohong Hong (22681698)
出版: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
由: Sanna Pikkusaari (15055802)
出版: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
由: Sanna Pikkusaari (15055802)
出版: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
由: Yufang Bao (15386826)
出版: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
由: Yufang Bao (15386826)
出版: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
由: Yufang Bao (15386826)
出版: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
由: Yufang Bao (15386826)
出版: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
由: Yufang Bao (15386826)
出版: (2025)

Supplementary Table 1 from <i>N<sup>6</sup></i>-Methyladenosine Promotes Translation of VEGFA to Accelerate Angiogenesis in Lung Cancer
由: Haisheng Zhang (16436982)
出版: (2025)

Source Data from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
由: Takeru Oka (15386810)
出版: (2025)

Supplementary Table S1 from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
由: Takeru Oka (15386810)
出版: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
由: Seung Yeon Oh (15051017)
出版: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
由: Nicole A. Traphagen (16677391)
出版: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
由: Nicole A. Traphagen (16677391)
出版: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
由: Alex C.H. Liu (14961921)
出版: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
由: Alex C.H. Liu (14961921)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_irc9i1m9i31qsquuvmhhjpk1d5